Adaptimmune Therapeutics ADAP
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.48Market Cap
$122.82 MillionPrice-Earnings Ratio
-16.00Total Outstanding Shares
1.54 Billion SharesTotal Employees
449Dividend
No dividendIPO Date
May 6, 2015SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
American Depository Receipt CommonHeadquarters
60 jubilee avenue, Abingdon, oxfordshire, X0, OX14 4RXHomepage
https://www.adaptimmune.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $78.82 Million |
| Net Cash Flow From Investing Activities, Continuing | $1.08 Million |
| Net Cash Flow | $26.35 Million |
| Net Cash Flow From Operating Activities, Continuing | $-53.68 Million |
| Net Cash Flow From Investing Activities | $1.08 Million |
| Net Cash Flow, Continuing | $26.22 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-44.52 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Research and Development | $143.17 Million |
| Income Tax Expense/Benefit | $1.23 Million |
| Benefits Costs and Expenses | $218.33 Million |
| Net Income/Loss Attributable To Parent | $-44.52 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $-5.24 Million |
| Other Comprehensive Income/Loss | $-23.19 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-49.75 Million |
| Comprehensive Income/Loss | $-50.09 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $228.18 Million |
| Current Liabilities | $63.46 Million |
| Equity | $79.99 Million |
| Liabilities And Equity | $317.44 Million |
| Prepaid Expenses | $14.16 Million |
| Intangible Assets | $4.28 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ADAP from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.